Moreover, our recent data suggests that selective proteasome inhibition also helps in controlling chronic inflammation that will be required for treating the patients with chronic lung disease, as rescuing misfolded CFTR may not be sufficient for favorable therapeutic outcome. This evidence concerns the gene CFTR and chronic lung disease.